


# Report on Costs and Outcomes of Medication-Assisted Treatment Programs Included in G.L. 127 § 17B

Massachusetts Department of Correction  
Submitted in Compliance with Chapter 127  
Section 17D of the Massachusetts General Laws





December 2020

## **Commonwealth of Massachusetts**

Charles D. Baker, Governor

## **Executive Office of Public Safety and Security**

Thomas A. Turco III, Secretary

## **Massachusetts Department of Correction**

Carol A. Mici, Commissioner

Rhiana Kohl, Ph.D., Executive Director of Strategic Planning & Research

Office of Strategic Planning and Research

### Data Analytics Unit

Director: Eva Yutkins-Kennedy

Brian DeMars

Ryan Fallon

Brian Giusti

Jesse Ross

Isaac Twum

# Table of Contents

Introduction ..... 4

Section 1 and Section 2..... 5

Section 3 ..... 6

Section 4 ..... 6

Section 5 ..... 7

Section 6 ..... 8

Section 7 ..... 8

Section 8 ..... 9

Section 9 ..... 9

Section 10 ..... 10

Section 11 ..... 10

## Introduction

---

Section 17D of Chapter 127 of the Massachusetts General Laws directs the Commissioner of Correction to report **annually**<sup>1</sup>, not later than February 1, on the costs and outcomes of Medication-Assisted Treatment programs included in Massachusetts General Laws Section 17B of Chapter 127 of the Massachusetts General Laws.

(i) the cost to the facility of providing medication-assisted treatment for opioid use disorder; (ii) the cost to the facility of providing re-entry treatment plans under section 17C; (iii) the type and prevalence of medication-assisted treatment provided for opioid use disorder; (iv) the number of persons in the custody of the facility, in any status, who continued to receive the same medication-assisted treatment as they received prior to incarceration, by medication type; (v) the number of persons in the custody of the facility, in any status, who changed or discontinued medication-assisted treatment for opioid use disorder that they received prior to incarceration, by medication type; (vi) the number of persons in the custody of the facility, in any status, who received medication-assisted treatment for opioid use disorder during the 90 days prior to release, by medication type; (vii) the number of persons in the custody of a facility, in any status, with a re-entry treatment plan that included medication-assisted treatment but did not receive such treatment prior to release; (viii) the number of persons in the custody of the facility, in any status, who received medication-assisted treatment for opioid use disorder who did not receive such treatment prior to incarceration, by medication type; (ix) a summary of facility practices and any changes to those practices related to medication-assisted treatment for opioid use disorder; (x) the number of persons who were connected to treatment after release; (xi) the number of persons who received a re-entry treatment plan under section 17C and were subsequently enrolled in MassHealth upon discharge; provided, however, that the commissioner, the commissioner of medical assistance and the commissioner of public health shall coordinate to provide such information; and (xii) any other information requested by the commissioner related to the provision of medication-assisted treatment for opioid use disorder.

---

<sup>1</sup> Data reflected in this report reflects October through December 2019. A uniform data collection process was established during 2019, which allowed for the data produced herein and thereafter.

## *MAT Program*

Medicated Assisted Treatment (MAT) combines medications with counseling and behavioral therapies, monitoring, community-based services, and recovery support to treat the bio-psychosocial aspects of alcohol and opioid use disorders.

### *FDA Approved Drugs for MAT*

#### **Methadone**

How it Works: Full Agonist

Medication Administration: Pill /Liquid

Dosing Frequency: Daily

Access to Medication: Opioid Treatment Program (OTP)

#### **Buprenorphine**

How it Works: Partial Agonist

Medication Administration: Pill/Film (Placed under the tongue, inside cheek) or Implant (Inserted beneath the skin)

Dosing Frequency: Pill/Film administered daily and Implant administered every 6 months

Access to Medication: A prescriber with the appropriate waiver

#### **Naltrexone**

How it Works: Antagonist

Medication Administration: Oral or Extended-release injectable

Dosing Frequency: Oral administered daily and Injectable administered monthly

Access to Medication: Any health care provider with prescribing authority

## **Section 1 and Section 2**

---

The cost to the facility<sup>2</sup> of providing medication-assisted treatment and re-entry treatment plans<sup>3</sup> for opioid use disorder.

<b><u>Time period:</u></b>	<b><u>MAT Medical</u></b>	<b><u>MAT Mental Health</u></b>	<b><u>Total:</u></b>
FY19 (Apr19- June19)	\$224,980.80	\$73,676.40	\$298,657.20
FY20 (Jul 19-Dec 19)	\$471,437.05	\$151,773.36	\$623,210.41

**Total: = \$921,867.61 (from April 19 thru Dec 19, 2019)**

---

<sup>2</sup> Reporting of costs to each facility is not available due to Wellpath's current billing structure per their contract.

<sup>3</sup> For the purposes of this report the cost of MAT (Section 1) and the cost of re-entry treatment plans (Section 2) have been combined.

## Section 3

Table 3 below reflects the type and prevalence of medication-assisted treatment provided for opioid use disorder.

**Table 3**

Facility	Month	Medication Type		
		Methadone	Buprenorphine	Naltrexone
MCI Cedar Junction	October 2019	0	12	0
	November 2019	1	10	0
	December 2019	0	7	0
MCI Framingham	October 2019	0	38	10
	November 2019	1	38	8
	December 2019	2	47	10
MA Alcohol & Substance Abuse Center	October 2019	0	71	18
	November 2019	0	88	12
	December 2019	0	42	8
South Middlesex CC	October 2019	0	17	5
	November 2019	0	9	4
	December 2019	0	11	5

## Section 4

Table 4 below reflects the number of persons in the custody of the facility, in any status, who continued to receive the same medication-assisted treatment as they received prior to incarceration, by medication type.

**Table 4**

Facility	Month	Medication Type		
		Methadone	Buprenorphine	Naltrexone
MCI Cedar Junction	October 2019	0	2	0
	November 2019	0	7	0
	December 2019	0	4	0
MCI Framingham	October 2019	0	25	0
	November 2019	1	41	0
	December 2019	0	16	0
MA Alcohol & Substance Abuse Center	October 2019	0	0	0
	November 2019	0	0	0
	December 2019	0	0	0
South Middlesex CC	October 2019	0	17	5
	November 2019	0	9	4
	December 2019	0	11	5

## Section 5

Table 5 below reflects the number of persons in the custody of the facility, in any status, who changed or discontinued medication-assisted treatment for opioid use disorder that they received prior to incarceration, by medication type.

**Table 5**

		Medication Type					
Facility	Month	Methadone Changed	Methadone Discontinued	Buprenorphine Changed	Buprenorphine Discontinued	Naltrexone Changed	Naltrexone Discontinued
MCI Cedar Junction	October 2019	0	0	14	0	0	0
	November 2019	1	0	0	0	0	0
	December 2019	0	0	0	0	0	0
MCI Framingham	October 2019	0	0	0	1	0	0
	November 2019	0	0	0	0	0	0
	December 2019	0	0	0	0	3	0
MA Alcohol & Substance Abuse Center	October 2019	0	0	16	3	0	0
	November 2019	0	0	12	6	2	1
	December 2019	0	0	14	6	1	0
South Middlesex CC	October 2019	0	0	0	0	0	0
	November 2019	0	0	0	0	0	0
	December 2019	0	0	0	0	0	0

## Section 6

Table 6 below reflects the number of persons in the custody of the facility, in any status, who received medication-assisted treatment for opioid use disorder during the 90 days prior to release, by medication type.

**Table 6**

<b>Facility</b>	<b>October 2019</b>	<b>November 2019</b>	<b>December 2019</b>
Boston Pre-Release Center	0	0	0
MCI Cedar Junction	4	9	8
MCI Concord	0	0	0
MCI Framingham	8	5	6
NCCI Gardner	0	0	0
MA Alcohol & Substance Abuse Center	128	116	58
MA Treatment Center	3	1	0
Northeastern CC	0	0	0
MCI Norfolk	1	0	0
Old Colony CC	4	1	0
Pondville CC	0	0	0
Souza-Baranowski CC	0	0	0
MCI Shirley	0	0	4
South Middlesex CC	5	3	3

## Section 7

Table 7 below reflects the number of persons in the custody of a facility, in any status, with a re-entry treatment plan that included medication-assisted treatment but did not receive such treatment prior to release.

**Table 7**

<b>Facility</b>	<b>October 2019</b>	<b>November 2019</b>	<b>December 2019</b>
Boston Pre-Release Center	3	0	0
MCI Cedar Junction	3	2	1
MCI Concord	6	1	4
MCI Framingham	0	0	0
NCCI Gardner	2	0	0
MA Alcohol & Substance Abuse Center	2	0	3
MA Treatment Center	1	0	1
Northeastern CC	1	3	0
MCI Norfolk	1	3	4
Old Colony CC	4	1	4
Pondville CC	3	0	2
Souza-Baranowski CC	7	5	6
MCI Shirley	3	3	2
South Middlesex CC	0	0	0



## Section 8

Table 8 below reflects the number of persons in the custody of the facility, in any status, who were prescribed medication-assisted treatment for opioid use disorder who did not receive such treatment prior to incarceration, by medication type.

**Table 8**

Facility	Month	Medication Type		
		Methadone	Buprenorphine	Naltrexone
MCI Cedar Junction	October 2019	0	12	0
	November 2019	0	10	0
	December 2019	0	7	0
MCI Framingham	October 2019	0	25	0
	November 2019	1	41	0
	December 2019	0	16	0
MA Alcohol & Substance Abuse Center	October 2019	0	17	12
	November 2019	0	12	6
	December 2019	0	2	4
South Middlesex CC	October 2019	0	0	2
	November 2019	0	0	0
	December 2019	0	0	0

## Section 9

Response 9 below reflects a summary of facility practices and any changes to those practices related to medication-assisted treatment for opioid use disorder.

### Response 9

This policy is intended to ensure that patients who have Opioid Use Disorder (OUD), and are willing to receive Medication-Assisted Treatment (MAT), do so based on feasibility per facility rules and Practitioner’s waiver to prescribe. This policy also addresses those with Alcohol Use Disorder (AUD) who are willing to receive MAT (naltrexone) for that diagnosis.

Upon admission, patients shall be screened by the Registered Nurse or Practitioner for OUD. Patients, who are willing and are appropriate candidates in facilities wherein buprenorphine is allowed, may be offered continuation or induction of MAT while incarcerated. Prescribing practitioners must have a special dispensation from the Drug Enforcement Agency in the form of a DEAx waiver. Options other than buprenorphine shall be presented to the patient where available. These other options include methadone, naltrexone and abstinence. Likewise, patients who enter correctional facilities on MAT shall have these medications continued as clinically indicated.

## Section 10

Table 10 below reflects the number of persons who were connected to treatment after release.

**Table 10**

<b>Facility</b>	<b>October 2019</b>	<b>November 2019</b>	<b>December 2019</b>
Boston Pre-Release Center	6	0	0
MCI Cedar Junction	14	22	18
MCI Concord	12	2	8
MCI Framingham	18	10	13
NCCI Gardner	4	0	0
MA Alcohol & Substance Abuse Center	165	157	94
MA Treatment Center	7	2	2
Northeastern CC	2	6	0
MCI Norfolk	4	6	8
Old Colony CC	16	4	8
Pondville CC	6	0	4
Souza-Baranowski CC	14	10	12
MCI Shirley	6	4	11
South Middlesex CC	8	6	6

## Section 11

Table 11 below reflects the number of persons who received a re-entry treatment plan under section 17C and were subsequently enrolled in MassHealth upon discharge; provided, however, that the commissioner, the commissioner of medical assistance and the commissioner of public health shall coordinate to provide such information.

**Table 11**

<b>Facility</b>	<b>October 2019</b>	<b>November 2019</b>	<b>December 2019</b>
Boston Pre-Release Center	3	0	0
MCI Cedar Junction	7	11	9
MCI Concord	6	1	4
MCI Framingham	10	5	7
NCCI Gardner	2	0	0
MA Alcohol & Substance Abuse Center	35	41	33
MA Treatment Center	3	1	1
Northeastern CC	1	3	0
MCI Norfolk	2	3	4
Old Colony CC	8	2	4
Pondville CC	3	0	2
Souza-Baranowski CC	7	5	6
MCI Shirley	3	1	5
South Middlesex CC	3	3	3